ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin

被引：16

作者：

Abid, Muhammad Bilal ^{[1
]}

Wang, Shi ^{[2
]}

Loi, Hoi Yin ^{[3
]}

Poon, L. M. ^{[1
]}

机构：

[1] Natl Univ Canc Inst Singapore NCIS, Dept Hematol Oncol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore

[2] Natl Univ Singapore Hosp, Dept Pathol, Singapore, Singapore

[3] Natl Univ Singapore Hosp, Dept Nucl Med, Singapore, Singapore

来源：

ANNALS OF HEMATOLOGY | 2016年 / 95卷 / 10期

关键词：

SGN-35;

D O I：

10.1007/s00277-016-2746-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1725 / 1726

页数：2

共 6 条

[1] Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin [J].

Chen, Xueyan ;

Soma, Lorinda A. ;

Fromm, Jonathan R. .

ONCOTARGETS AND THERAPY, 2014, 7 :45-56

[2] cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [J].

Francisco, JA ;

Cerveny, CG ;

Meyer, DL ;

Mixan, BJ ;

Klussman, K ;

Chace, DF ;

Rejniak, SX ;

Gordon, KA ;

DeBlanc, R ;

Toki, BE ;

Law, CL ;

Doronina, SO ;

Siegall, CB ;

Senter, PD ;

Wahl, AF .

BLOOD, 2003, 102 (04) :1458-1465

[3] Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma [J].

Gascoyne, RD ;

Aoun, P ;

Wu, D ;

Chhanabhai, M ;

Skinnider, BF ;

Greiner, TC ;

Morris, SW ;

Connors, JM ;

Vose, JM ;

Viswanatha, DS ;

Coldman, A ;

Weisenburger, DD .

BLOOD, 1999, 93 (11) :3913-3921

[4] Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study [J].

Pro, Barbara ;

Advani, Ranjana ;

Brice, Pauline ;

Bartlett, Nancy L. ;

Rosenblatt, Joseph D. ;

Illidge, Tim ;

Matous, Jeffrey ;

Ramchandren, Radhakrishnan ;

Fanale, Michelle ;

Connors, Joseph M. ;

Yang, Yin ;

Sievers, Eric L. ;

Kennedy, Dana A. ;

Shustov, Andrei .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) :2190-2196

[5] ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:: report from the International Peripheral T-Cell Lymphoma Project [J].

Savage, Kerry J. ;

Harris, Nancy Lee ;

Vose, Julie M. ;

Ullrich, Fred ;

Jaffe, Elaine S. ;

Connors, Joseph M. ;

Rimsza, Lisa ;

Pileri, Stefano A. ;

Chhanabhai, Mukesh ;

Gascoyne, Randy D. ;

Armitage, James O. ;

Weisenburger, Dennis D. .

BLOOD, 2008, 111 (12) :5496-5504

[6] Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. [J].

Younes, Anas ;

Bartlett, Nancy L. ;

Leonard, John P. ;

Kennedy, Dana A. ;

Lynch, Carmel M. ;

Sievers, Eric L. ;

Forero-Torres, Andres .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) :1812-1821

← 1 →